Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Avrobio, Inc. Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

$92.2 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$3.45 - $6.05 $119,056 - $208,779	-34,509 Closed	0 $0
Q3 2021 Nov 04, 2021	BUY	$5.53 - $9.28 $5,574 - $9,354	1,008 Added 3.01%	34,509 $193,000
Q2 2021 Aug 06, 2021	BUY	$7.84 - $12.6 $101,974 - $163,888	13,007 Added 63.47%	33,501 $298,000
Q1 2021 May 06, 2021	BUY	$10.54 - $19.3 $75,940 - $139,056	7,205 Added 54.22%	20,494 $260,000
Q4 2020 Feb 09, 2021	BUY	$12.79 - $17.1 $11,140 - $14,894	871 Added 7.01%	13,289 $185,000
Q3 2020 Nov 10, 2020	SELL	$12.99 - $19.41 $12 - $19	-1 Reduced 0.01%	12,418 $162,000
Q2 2020 Aug 06, 2020	BUY	$12.19 - $22.96 $151,387 - $285,140	12,419 New	12,419 $217,000

Others Institutions Holding AVRO

# of Institutions

Shares Held

559K

Call Options Held

Put Options Held

Terrapin Asset Management, LLC Miami, FL

559K
Shares

$0
0.98% of portfolio

View Full List

About AVROBIO, Inc.

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

More about AVRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Account